En tous cas, le Mg (Tiens: Mg = Michel garner) n'est certainement pas considéré comme un anti-arythmique. Au mieux il ralentit la fréquence, mais par un mécanisme mal connu (j'en parlais ce jour avec le chef de notre service d'arythmologie), mais il n'a aucun propriété anti-arythimique digne de ce nom. Alain.
_____ From: [email protected] [mailto:[EMAIL PROTECTED] On Behalf Of Michael Garner Sent: 24 septembre 2007 14:55 To: [email protected] Subject: URG-L: Re: URG-L: RE: URG-L: Magnésium et FA Très intéressant, mais si ça augmente les chances de contrôler à la fois la fréquence et le rythme, ça suggère que l'on puisse risquer de convertir des FA chroniques, avec les risques associés d'embolie. On ne devrait logiquement ne s'en servir que dans les FA aigues, en autant que l'on puisse être certain qu'une FA est aigue Ou suis-je dans les pommes de terre ? (puisque la France nous lit, je ne voudrai pas les dérouter avec des termes comme patates) Michel Garner On 16-Sep-07, at 5:49 PM, Alain Vadeboncoeur wrote: Très intéressant. Am J Cardiol. 2007 Jun 15;99(12):1726-32. Epub 2007 Apr 26.<http---linkinghub.elsevier.com-ihub-images-PubMedLink.gif> Links Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I. Arrhythmia Services, Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada. [EMAIL PROTECTED] The profile of electrophysiologic effects of magnesium on the heart suggests that magnesium might be effective in the treatment of atrial fibrillation (AF) in terms of rhythm and rate control. We aimed to investigate the efficacy of magnesium administration in the acute treatment of rapid AF. Randomized controlled trials comparing intravenous magnesium versus placebo or antiarrhythmic agents for the acute management of rapid AF were included. Nine electronic databases were searched for relevant trials from the earliest possible dates through June 2005, as were abstract books from 8 cardiovascular meetings held in the past 10 years. We analyzed all outcomes using a fixed-effect model because of the low number of trials in each comparison. The results were expressed as relative risks (RRs) or odds ratios (ORs) for dichotomous outcomes and weighted mean differences for continuous outcomes, along with their 95% confidence intervals (CIs). Data were pooled for 4 trials (n=303) and 8 trials (n=476), respectively, for rate control (<100 beats/min) and rhythm control. Magnesium was effective in achieving rate control (OR 1.96, 95% CI 1.24 to 3.08) or rhythm control (OR, 1.60, 95% CI 1.07 to 2.39). An overall response was achieved in 86% and 56% of patients in the magnesium and control groups, respectively (OR 4.61 95% CI 2.67 to 7.96). Time to response (in hours) was significantly shorter in the magnesium group (weighted mean difference, -6.98; 95% CI -9.27 to -4.68). The risk of having a major adverse effect in the magnesium group was similar to that in the placebo group (RR 0.85, 95% CI 0.44 to 1.61). In conclusion, the present meta-analysis of published data suggests that intravenous magnesium administration is an effective and safe strategy for the acute management of rapid AF. J'avais déjà essayé une fois, il y a longtemps. Je m'y mets dès cette semaine. Alain From: [email protected] [mailto:[EMAIL PROTECTED] On Behalf Of Martin Chénier Sent: 16 septembre 2007 15:23 To: [email protected] Subject: URG-L: Magnésium et FA Est-ce que certains d'entre vous ont lu l'article suivant : Meta-Analysis of Magnesium Therapy for the Acute Management of Rapid Atrial Fibrillation. Am J Cardiol 2007;99:1726-1732. Utilisez-vous le sulfate de Mg dans la FA/Flutter rapide? -- Martin Chénier [EMAIL PROTECTED]
